Rakovina Therapeutics

News & Media

Press Releases

April 27, 2022: Rakovina Therapeutics Inc. Announces 2021 Financial Results and Provides Corporate Update

April 12, 2022: Rakovina Therapeutics Presents Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research (AACR)

March 30, 2022: Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference – Sarcomas

March 09, 2022: Rakovina Therapeutics to Present Abstract at the 2022 Annual Meeting of the American Association of Cancer Research (AACR)

February 21, 2022: Rakovina Therapeutics preventing cancer cells from making DNA repairs they need to survive

January 25, 2022: Rakovina Therapeutics President to Join Expert Panel at the Fifth Annual DDR, ATR & PARP Inhibitors Summit

January 06, 2022: Rakovina Therapeutics Inc. to Present at Biotech Showcase 2022

December 21, 2021: Rakovina Therapeutics Announces Non-dilutive Financial Contributions to Support Lead Optimization of Novel Anti-cancer Agents

November 23, 2021: Rakovina Therapeutics Inc. Announces Third Quarter 2021 Financial Results and Provides Corporate Update

November 16, 2021: Rakovina Therapeutics Partners with St. Baldrick’s Foundation to Research and Develop New Treatments for Childhood Bone Cancer

November 11, 2021: Rakovina Therapeutics Presents at the 6th biennial Canadian Cancer Research Conference

October 21, 2021: Rakovina Therapeutics to Present at the 6th biennial Canadian Cancer Research Conference

October 12, 2021: Rakovina Therapeutics Presents at the 2021 AACRNCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

October 7, 2021: Rakovina Therapeutics Inc. Receives Notice of Allowance for New U.S. Patent Covering kt-2000 series PARP Inhibitors

September 16, 2021: Rakovina Therapeutics Presents Preclinical Data on novel kt-3000 Series Drug Candidates at JCA-AACR Precision Medicine International Conference 

September 9, 2021: Rakovina Therapeutics to Present at the JCA-AACR Precision Medicine International Conference 

August 26, 2021: Rakovina Therapeutics Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate Update

August 17, 2021: Rakovina Therapeutics to Present at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

June 29, 2021: Rakovina Therapeutics Announces Results from Annual General Meeting

June 17, 2021: Rakovina Therapeutics to Present at at The Emerging Growth Conference on June 23, 2021

May 27, 2021: Rakovina Therapeutics Inc. Announces First Quarter 2021 Financial Results and Provides Corporate Update

April 29, 2021: Rakovina Therapeutics Inc. Announces Inaugural Scientific Advisory Board

April 8, 2021: Rakovina Therapeutics Inc. Receives European and Canadian Patents on kt-2000 series PARP-inhibitors

April 5, 2021: Rakovina Therapeutics Inc. Appoints Biotechnology Industry Veteran Julie M. Cherrington, PhD to Board of Directors

April 1, 2021: Rakovina Therapeutics Inc. Commences Trading on TSX Venture Exchange Under Ticker Symbol “RKV”

March 25, 2021: Rakovina Therapeutics Inc. (Formerly Vincero Capital Corp.) Announces Closing of Qualifying Transaction

March 19, 2021: Vincero Capital Corp. Announces Filing of Filing Statement in Connection with Qualifying Transaction

March 12, 2021:  Vincero Capital Corp. Receives Conditional Approval of TSX Venture Exchange for Qualifying Transaction with NewGen Therapeutics, Inc. and Announces Over-Subscribed Financing

November 10, 2020:  Vincero Capital Provides Update on Qualifying Transaction